Structured evidence table for Choline Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Choline Cognitive Performance Randomized Trial | It is commonly defined as the presence of clinically relevant depressive symptoms that do not meet the full diagnostic criteria for major depressive disorder (MDD) yet are associated with measurable distress and functional impairment [,]. | 4 | Fleishhacker Filippo (2026) | Choline Alfoscerate in the Treatment of Subthreshold Depression in the Elderly: A Pilot Study (CARTESIO) |
| Choline Cognitive Performance Randomized Trial | Recent meta-analytic evidence indicates that subthreshold depressive symptoms affect nearly 15–20% of older individuals, with higher prevalence rates observed in primary care and institutional settings [,]. | 4 | Fleishhacker Filippo (2026) | Choline Alfoscerate in the Treatment of Subthreshold Depression in the Elderly: A Pilot Study (CARTESIO) |
| Choline Cognitive Performance Randomized Trial | Importantly, SD is not a benign condition; rather, it represents a clinically meaningful syndrome associated with increased morbidity and reduced quality of life []. | 4 | Fleishhacker Filippo (2026) | Choline Alfoscerate in the Treatment of Subthreshold Depression in the Elderly: A Pilot Study (CARTESIO) |
| Choline Cognitive Performance Randomized Trial | 1 2 3 4 5 6 Subthreshold depression (SD) is a highly prevalent and clinically significant condition among older adults. | 4 | Fleishhacker Filippo (2026) | Choline Alfoscerate in the Treatment of Subthreshold Depression in the Elderly: A Pilot Study (CARTESIO) |
| Choline Cognitive Performance Randomized Trial | This narrative review summarizes current preclinical and clinical evidence regarding the mechanistic and clinical relevance of L-α-GPC in neurodegenerative disorders associated with cognitive impairment. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Choline Cognitive Performance Randomized Trial | In animal models, L-α-GPC has been associated with improved cognitive performance, reduced neuroinflammation, and attenuation of amyloid-β and tau-related pathological features. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Choline Cognitive Performance Randomized Trial | However, the interpretation of these findings should be cautious because the available evidence remains heterogeneous, with notable variability in study design, dosage regimens, treatment duration, and outcome measures. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Choline Cognitive Performance Randomized Trial | Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia are characterized by progressive neuronal loss, synaptic dysfunction, and cognitive decline. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
Source documents